T Lymphocyte Activation Antigen CD80 Market

Global T Lymphocyte Activation Antigen CD80 Market Size, Share and Trends Analysis Report, By Type (Abatacept, Abatacept Biosimilar, CUE-201, KAHR-102, and Others), By Application (Metabolic Disorders, Autoimmune Disorders, Acute Myelocytic Leukemia, and Others), Forecast (2022-2028)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2026095 | Category : Healthcare Information Technology | Delivery Format: /

The global T lymphocyte activation antigen CD80 market is anticipated to grow at a significant CAGR 3.3% during the forecast period (2022-2028). CD80 is a costimulatory molecule that is known for its role in T-cell activation. It also regulates the activity of normal and malignant B cells. The major factor driving the demand for T lymphocyte activation antigen CD80 is the increasing prevalence of acute myelocytic leukemia (AML) across the globe. 

According to the American Society of Clinical Oncology (ASCO), AML is uncommon and makes up about 1% of cancers. Additionally, in 2021, an estimated 20,240 people of all ages which include 11,230 men and boys and 9,010 women and girls was diagnosed with AML in the US. Furthermore, AML is the second most common type of leukemia diagnosed in adults and children, however, most cases occur in adults and makes up 31% of all adult leukemia cases. Moreover, the average age of diagnosis is 68 years, however, it can be diagnosed at any age. Hence, the increasing prevalence of AML is driving the demand for T lymphocyte activation antigen CD80 as it is used as immunotherapy by identifying neoplastic cells and sparing healthy tissue which in turn is driving the growth of the market.

Some major players in the market include Bristol-Myers Squibb Co, and KAHR Medical Ltd, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in October 2021, AstraZeneca announced positive high-level results from the Phase III Himalaya clinical trial of Imfinzi (durvalumab) plus tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (HCC) patients. Tremelimumab is an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody.

Market Coverage

The market number available for – 2021-2028

Base year- 2021

Forecast period- 2022-2028

Segment Covered- 

o By Type

o By Application

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- Bristol-Myers Squibb Co, and KAHR Medical Ltd, among others.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How players are addressing challenges to sustain growth?

Where is the investment opportunity?

Global T Lymphocyte Activation Antigen CD80 Market Report by Segment

By Type

Abatacept

Abatacept Biosimilar

CUE-201

KAHR-102

Others

By Application 

Metabolic Disorders

Autoimmune Disorders

Acute Myelocytic Leukemia

Others

Global T Lymphocyte Activation Antigen CD80 Market Report by Region

North America

United States

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe 

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific 

Rest of the World

Latin America 

Middle East & Africa